

## In a Fast-Moving Industry, Stay Up-to-Date on the Happenings. Here are Our Favorite Stories from December 2022.

### Funding Updates:

- 12.01.22 - Scientists at UCSD Receive \$4.8M to Pursue Gene Therapy for 'Incurable' Disease ([today.ucsd](#))
- 12.01.22 - Lundbeck-partnered preclinical biotech nabs Series A from AstraZeneca ([Endpts](#))
- 12.07.22 - Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of \$115.8 Million ([PR](#))
- 12.07.22 - ExPLoRNA Therapeutics Receives Funding to Advance its Novel mRNA Technology ([PR](#))
- 12.08.22 - Cabaletta Bio Announces \$35 Million Offering ([PR](#))
- 12.08.22 - Autolus Therapeutics to Receive \$70 Million in Milestone Payments from Blackstone Life Sciences ([PR](#))
- 12.08.22 - SonoThera™ Completes \$60.75M Series A Funding for Ultrasound-Guided, Nonviral Gene Therapy Platform Development ([PR](#))
- 12.12.22 - Gamida Cell Announces Closing of \$25 Million Financing With Highbridge ([PR](#))
- 12.13.22 - Flagship Pioneering Unveils Montai Health to Treat and Prevent Chronic Disease Afflicting Two Billion People Worldwide ([PR](#))
- 12.14.22 - Replay targets genetic brain disorders with new gene therapy company, Kaleibe, utilizing big DNA HSV technology ([Biospace](#))
- 12.15.22 - Enlaza Therapeutics Launches with \$61 Million Seed Financing to Advance the First Covalent Biologic Therapeutic Platform ([PR](#))
- 12.15.22 - Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock ([PR](#))
- 12.19.22 - A2 Biotherapeutics raises \$62M for solid tumor cell therapies ([Endpts](#))
- 12.19.22 - Protillion Biosciences Closes \$18M Series A Round ([genomeweb](#))
- 12.21.22 - Aspen Neuroscience Inks \$40 Million Debt Deal with Silicon Valley Bank ([PR](#))
- 12.21.22 - Quris reels in \$9M in seed funding to support AI innovations in trials ([Fiercebiotech](#))

### Manufacturing & CDMO Updates:

- 12.08.22 - The CDMO space does not have the capacity to meet fill-finish demand, says Lonza ([Bioprocessintl](#))
- 12.13.22 - Fujifilm's Life Sciences Corporate Venture Capital Fund Invests in PhenoVista Biosciences ([PR](#))
- Catalent to Expand Its Biologics Analytical Services with New Facility in Durham, North Carolina ([LifeSciKnowledgeHub](#))
- 12.20.22 - SCORPION BIOLOGICAL SERVICES BECOMES SCORPIUS BIOMANUFACTURING TO REFLECT EXPANSION ([PR](#))
- 01.02.22 - Polysciences Announces New Bioprocessing Brand, Kyfora Bio ([PR](#))

### Private Equity & VC Fund Updates:

- 12.06.22 - Avalon BioVentures Raises First Fund Dedicated to Early-Stage Biotech Investments ([PR](#))

### Clinical and Commercial Milestones:

- 12.01.22 - SparingVision's lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa ([PR](#))
- 12.02.22 - Opus Genetics Receives FDA Clearance of IND Application for OPGx-001, a Gene Therapy Candidate Intended for the Treatment of Rare Inherited Retinal Disease LCA5 ([PR](#))
- 12.06.22 - SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress ([PR](#))
- 12.06.22 - Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus ([PR](#))
- 12.06.22 - Editas Medicine Announces Positive Safety And Efficacy Data From The First Two Patients Treated In The RUBY Trial Of EDIT-301 For The Treatment Of Severe Sickle Cell Disease ([PR](#))
- 12.06.22 - BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure ([PR](#))
- 12.07.22 - NKARTA ANNOUNCES UPDATED CLINICAL DATA ON ANTI-CD19 ALLOGENEIC CAR-NK CELL THERAPY NKX019 FOR PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA ([PR](#))
- 12.07.22 - First AML Patient Successfully Transplanted with Vor Bio's Investigational Trem-cel (VOR33) and Tolerated Mylotarg™ ([PR](#))
- 12.07.22 - AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy ([PR](#))
- 12.08.22 - REGENXBIO ANNOUNCES COMPLETION OF DOSING IN THE PHASE I/II TRIAL OF RGX-111 FOR THE TREATMENT OF SEVERE MPS I ([PR](#))
- 12.09.22 - Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma ([PR](#))

- 12.12.22 - Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIa ([PR](#))
- 12.12.22 - Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A ([PR](#))
- 12.12.22 - SwanBio Therapeutics Initiates First-in-Human Study of AAV Gene Therapy for Adrenomyeloneuropathy ([PR](#))
- 12.12.22 - Vertex, Moderna prepare to take their inhaled mRNA cystic fibrosis drug into the clinic ([Endpts](#))
- 12.13.22 - Moderna vaccine succeeds in early-stage skin cancer study with Merck's Keytruda ([Biopharmadive](#))
- 12.14.22 - PASSAGE BIO ANNOUNCES POSITIVE INTERIM CLINICAL DATA FROM FIRST SIX PATIENTS WITH GM1 GANGLIOSIDOSIS IN IMAGINE-1 STUDY ([PR](#))
- 12.14.22 - Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B ([PR](#))
- 12.16.22 - FDA Approves First Gene Therapy for the Treatment of High-Risk, Non-Muscle-Invasive Bladder Cancer ([FDA](#))
- 12.19.22 - Neurophth Receives IND Clearance from FDA for AAV-ND1 Gene Therapy of LHON ([PR](#))
- 12.19.22 - Ferring grabs first gene therapy approval in bladder cancer ([Pharmamanufacturing](#))
- 12.19.22 - FDA lifts hold on Bluebird's sickle cell gene therapy ([Biopharmadive](#))
- 12.29.22 - Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate ([PR](#))
- 12.29.22 - Gene Therapy for ART-SCID Shows "Amazing" Results in 10 Children ([genengnews](#))

### Collaboration Updates:

- 12.02.22 - Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta TCR ImmTAC for Solid Tumors ([PR](#))
- 12.05.22 - MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases ([PR](#))
- 12.08.22 - Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1) ([PR](#))
- 12.08.22 - Actinium Pharmaceuticals, Inc. Announces Research Collaboration with Columbia University to Study Actimab-A in AML Patients Following Transplant of Engineered Hematopoietic Stem Cells Gene Edited to be CD33 Negative ([PR](#))
- 12.13.22 - Wave Life Sciences to receive \$170M upfront in new partnership with GSK to develop a large number of candidates ([Endpts](#))
- 12.14.22 - Oxford Biomedica Solutions forms new partnerships with three biotechnology companies ([Biospace](#))
- 12.15.22 - GenScript and Avectas aim to reduce the cost of non-viral cell engineering ([PR](#))
- 12.15.22 - Evotec achieves further progress in neuroscience collaboration with Bristol Myers Squibb ([PR](#))
- 12.15.22 - Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh ([PR](#))
- 12.15.22 - Ori Biotech and Inceptor Bio partner to accelerate solid tumor cell therapy access ([PR](#))
- 12.19.22 - Arrowhead Pharmaceuticals Announces \$25 Million Milestone Payment from Amgen ([PR](#))
- 12.22.22 - Eli Lilly Expands RNA Editing Collaboration with ProQR Therapeutics ([Biospace](#))

### M&A Updates:

- 12.01.22 - Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation ([PR](#))
- 12.01.22 - Rocket Pharmaceuticals Completes Acquisition of Renovacor ([PR](#))
- 12.01.22 - Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases for \$487M buyout expands its gene therapy scope to hearing loss ([PR](#))
- 12.05.22 - Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent \$75 Million Private Placement ([PR](#))
- 12.06.22 - MilliporeSigma Gains Leading Perfusion Micro-Bioreactor with Erbi Biosystems Acquisition ([PR](#))
- 12.08.22 - Polyplus announces completion of acquisition of Xpress Biologics to expand plasmid DNA ([PR](#))
- 12.20.22 - Integrated DNA Technologies Acquires ArcherDX Next Generation Sequencing Research Assays from Invitae Corporation ([PR](#))
- 12.20.22 - Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer ([PR](#))
- 12.29.22 - Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger ([PR](#))
- 12.30.22 - Prenetics Announces Acquisition of ACT Genomics, Aiming for the Multi-billion Market of Precision Oncology ([InsidePrecisionMedicine](#))

For Inquiries or More Information, Contact Bryan Kennedy  
at [Bk@Projectevolution.org](mailto:Bk@Projectevolution.org)



[PROJECTEVOLUTION.ORG](http://PROJECTEVOLUTION.ORG)